| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Magdalena Świądro-Piętoń, Dominika Dudek, Renata Wietecha-Posłuszn. Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338419. |
it has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. |
2024-02-10 |
2024-02-12 |
Not clear |
| Elizabeth Mostel, Savan Patel, Brian G Wiene. A 70-Year-Old Woman Presenting with Confusion and Muscle Spasms Due to Serotonin Syndrome Associated with Paroxetine and Quetiapine Treatment. The American journal of case reports. vol 23. 2022-11-11. PMID:36366736. |
this report is of a 70-year-old woman who presented with confusion and muscle spasms due to serotonin toxicity associated with paroxetine and quetiapine treatment. |
2022-11-11 |
2023-08-14 |
Not clear |
| Elizabeth Mostel, Savan Patel, Brian G Wiene. A 70-Year-Old Woman Presenting with Confusion and Muscle Spasms Due to Serotonin Syndrome Associated with Paroxetine and Quetiapine Treatment. The American journal of case reports. vol 23. 2022-11-11. PMID:36366736. |
a 70-year-old woman presenting with confusion and muscle spasms due to serotonin syndrome associated with paroxetine and quetiapine treatment. |
2022-11-11 |
2023-08-14 |
Not clear |
| Elizabeth Mostel, Savan Patel, Brian G Wiene. A 70-Year-Old Woman Presenting with Confusion and Muscle Spasms Due to Serotonin Syndrome Associated with Paroxetine and Quetiapine Treatment. The American journal of case reports. vol 23. 2022-11-11. PMID:36366736. |
a presumptive diagnosis of serotonin toxicity was made early on during her stay, with the etiology attributed to use of paroxetine and quetiapine. |
2022-11-11 |
2023-08-14 |
Not clear |
| Alexander Ionov, Inger Boeck, Stefan Georg Schröde. [Electroconvulsive Therapy (ECT) in Neuroleptic Malignant Syndrome (NMS) on an Intensive Care Unit (ICU)]. Psychiatrische Praxis. 2022-01-26. PMID:35081629. |
several psychotropic drugs were on the medication list (quetiapine 450 mg/d, paroxetine 40 mg/d and perphenazine 12 mg/d), due to depression with psychotic features. |
2022-01-26 |
2023-08-13 |
Not clear |
| L Ilhan Yargic, Aytul Corapcioglu, Nese Kocabasoglu, Ayten Erdogan, Gulsah Koroglu, Dilek Yilma. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International journal of psychiatry in clinical practice. vol 8. issue 4. 2014-06-17. PMID:24930548. |
objective to evaluate quetiapine as an adjunct to paroxetine in patients with comorbid depression and anxiety. |
2014-06-17 |
2023-08-13 |
Not clear |
| L Ilhan Yargic, Aytul Corapcioglu, Nese Kocabasoglu, Ayten Erdogan, Gulsah Koroglu, Dilek Yilma. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International journal of psychiatry in clinical practice. vol 8. issue 4. 2014-06-17. PMID:24930548. |
conclusion quetiapine added to paroxetine is well tolerated and may speed up and improve response in patients with comorbid depression and anxiety. |
2014-06-17 |
2023-08-13 |
Not clear |
| L Ilhan Yargic, Aytul Corapcioglu, Nese Kocabasoglu, Ayten Erdogan, Gulsah Koroglu, Dilek Yilma. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International journal of psychiatry in clinical practice. vol 8. issue 4. 2014-06-17. PMID:24930548. |
a prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. |
2014-06-17 |
2023-08-13 |
Not clear |
| Klaus Seppi, Daniel Weintraub, Miguel Coelho, Santiago Perez-Lloret, Susan H Fox, Regina Katzenschlager, Eva-Maria Hametner, Werner Poewe, Olivier Rascol, Christopher G Goetz, Cristina Sampai. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 26 Suppl 3. 2012-02-27. PMID:22021174. |
this includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (ssris) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω-3 fatty acids as well as repetitive transcranial magnetic stimulation (rtms) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (cr), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. |
2012-02-27 |
2023-08-12 |
Not clear |
| Kuan-Ju Chou, Po-Yu Chen, Ming-Chyi Huan. Restless legs syndrome following the combined use of quetiapine and paroxetine. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 6. 2010-11-02. PMID:20470847. |
restless legs syndrome following the combined use of quetiapine and paroxetine. |
2010-11-02 |
2023-08-12 |
Not clear |
| Borwin Bandelow, Guy Chouinard, Julio Bobes, Antti Ahokas, Ivan Eggens, Sherry Liu, Hans Eriksso. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. The international journal of neuropsychopharmacology. vol 13. issue 3. 2010-06-24. PMID:19691907. |
the most common adverse events (aes) were dry mouth, somnolence, fatigue, dizziness, and headache, for quetiapine xr, and nausea, headache, dizziness for paroxetine. |
2010-06-24 |
2023-08-12 |
Not clear |
| Borwin Bandelow, Guy Chouinard, Julio Bobes, Antti Ahokas, Ivan Eggens, Sherry Liu, Hans Eriksso. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. The international journal of neuropsychopharmacology. vol 13. issue 3. 2010-06-24. PMID:19691907. |
the incidence of aes potentially related to extrapyramidal symptoms was: quetiapine xr: 50 mg, 6.8%, 150 mg, 5.0%; placebo, 1.8%; and paroxetine, 8.4%. |
2010-06-24 |
2023-08-12 |
Not clear |
| Susan L McElroy, Richard H Weisler, William Chang, Bengt Olausson, Björn Paulsson, Martin Brecher, Vasavan Agambaram, Charles Merideth, Arvid Nordenhem, Allan H Youn. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). The Journal of clinical psychiatry. vol 71. issue 2. 2010-04-22. PMID:20122366. |
a double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (embolden ii). |
2010-04-22 |
2023-08-12 |
Not clear |
| Susan L McElroy, Richard H Weisler, William Chang, Bengt Olausson, Björn Paulsson, Martin Brecher, Vasavan Agambaram, Charles Merideth, Arvid Nordenhem, Allan H Youn. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). The Journal of clinical psychiatry. vol 71. issue 2. 2010-04-22. PMID:20122366. |
the aim of this study was to evaluate the efficacy and tolerability of quetiapine and paroxetine monotherapy for major depression in bipolar disorder. |
2010-04-22 |
2023-08-12 |
Not clear |
| Naomi M Simon, Kathryn M Connor, Richard T LeBeau, Elizabeth A Hoge, John J Worthington, Wei Zhang, Jonathan R T Davidson, Mark H Pollac. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology. vol 197. issue 4. 2008-08-29. PMID:18246327. |
quetiapine augmentation of paroxetine cr for the treatment of refractory generalized anxiety disorder: preliminary findings. |
2008-08-29 |
2023-08-12 |
Not clear |
| Gabriele Mas. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS drugs. vol 18. issue 14. 2004-12-29. PMID:15584771. |
pharmacological, efficacy and safety data on drugs acting on serotonin (serotonergic agents such as clomipramine, fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine), on both serotonin and norepinephrine (venlafaxine and mirtazapine), dopamine (dopamine-blocking antipsychotics such as haloperidol and pimozide), and on both serotonin and dopamine (atypical antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and ziprasidone) are presented. |
2004-12-29 |
2023-08-12 |
Not clear |
| Richard E Kast, Eric Lewin Altschule. Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma. Medical hypotheses. vol 62. issue 5. 2004-11-30. PMID:15082113. |
here we note that the safe, approved and commonly used psychiatric medicines bupropion (wellbutrin), paroxetine (paxil) and quetiapine (seroquel) are respectively potent tnf, nitric oxide and histamine antagonists and thus might find some use in treatment of multiple myeloma. |
2004-11-30 |
2023-08-12 |
Not clear |
| Nadeem H Bhanji, Howard C Margoles. Extrapyramidal symptoms related to adjunctive nizatidine therapy in an adolescent receiving quetiapine and paroxetine. Pharmacotherapy. vol 24. issue 7. 2004-11-04. PMID:15303455. |
we describe, however, an adolescent who was receiving quetiapine and paroxetine for schizophrenia and depression, and developed extrapyramidal symptoms (eps; parkinsonism and akathisia) after taking nizatidine for weight loss. |
2004-11-04 |
2023-08-12 |
Not clear |
| F I Tarazi, K Zhang, R J Baldessarin. Olanzapine, quetiapine, and risperidone: long-term effects on monoamine transporters in rat forebrain. Neuroscience letters. vol 287. issue 2. 2000-08-17. PMID:10854717. |
we compared labeling of dopamine (dat) and serotonin (sert) transporter proteins in subregions of rat corpus striatum by quantitative autoradiography with [(3)h]2-beta-carbomethoxy-3-beta-[4'-iodophenyl]tropane ([(3)h]beta-cit) and [(3)h]paroxetine after 28 days of continuous subcutaneous infusion of olanzapine, quetiapine, risperidone, or vehicle controls. |
2000-08-17 |
2023-08-12 |
rat |